IBB vs. XLV
Compare and contrast key facts about iShares Nasdaq Biotechnology ETF (IBB) and Health Care Select Sector SPDR Fund (XLV).
IBB and XLV are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. IBB is a passively managed fund by iShares that tracks the performance of the NASDAQ Biotechnology Index. It was launched on Feb 5, 2001. XLV is a passively managed fund by State Street that tracks the performance of the Health Care Select Sector. It was launched on Dec 16, 1998. Both IBB and XLV are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: IBB or XLV.
Key characteristics
| IBB | XLV | |
|---|---|---|
| YTD Return | -3.74% | 3.38% |
| 1Y Return | 0.29% | 6.99% |
| 3Y Return (Ann) | -5.22% | 6.26% |
| 5Y Return (Ann) | 4.18% | 11.20% |
| 10Y Return (Ann) | 5.57% | 11.02% |
| Sharpe Ratio | 0.06 | 0.65 |
| Daily Std Dev | 16.65% | 10.53% |
| Max Drawdown | -62.85% | -39.18% |
| Current Drawdown | -25.26% | -4.91% |
Correlation
The correlation between IBB and XLV is 0.73, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
IBB vs. XLV - Performance Comparison
In the year-to-date period, IBB achieves a -3.74% return, which is significantly lower than XLV's 3.38% return. Over the past 10 years, IBB has underperformed XLV with an annualized return of 5.57%, while XLV has yielded a comparatively higher 11.02% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
IBB vs. XLV - Expense Ratio Comparison
IBB has a 0.47% expense ratio, which is higher than XLV's 0.12% expense ratio.
Risk-Adjusted Performance
IBB vs. XLV - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and Health Care Select Sector SPDR Fund (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
IBB vs. XLV - Dividend Comparison
IBB's dividend yield for the trailing twelve months is around 0.31%, less than XLV's 1.57% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | 0.31% | 0.26% | 0.31% | 0.21% | 0.21% | 0.17% | 0.20% | 0.30% | 0.19% | 0.03% | 0.15% | 0.03% |
XLV Health Care Select Sector SPDR Fund | 1.57% | 1.59% | 1.47% | 1.33% | 1.49% | 2.16% | 1.56% | 1.46% | 1.59% | 1.43% | 1.34% | 1.51% |
Drawdowns
IBB vs. XLV - Drawdown Comparison
The maximum IBB drawdown since its inception was -62.85%, which is greater than XLV's maximum drawdown of -39.18%. Use the drawdown chart below to compare losses from any high point for IBB and XLV. For additional features, visit the drawdowns tool.
Volatility
IBB vs. XLV - Volatility Comparison
iShares Nasdaq Biotechnology ETF (IBB) has a higher volatility of 5.66% compared to Health Care Select Sector SPDR Fund (XLV) at 3.14%. This indicates that IBB's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.